Among these ten trials, four focused on hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (HR+, HER2-), one focused on HER2-positive breast cancer only, two studies recruited patients of multiple breast cancer subtypes, and three studies made no mention of the patients’ subtype. Here, ERBB2 is linked to breast cancer.